TECH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

290.22M

-2.29%

0.434

+3.36%

321.84M

+1.79%

0.564

+0.74%

326.59M

+3.04%

0.561

+5.92%

Estimates Revision

The market is revising Downward the revenue expectations for Bio-Techne Corporation (TECH) for FY2026, with the revenue forecasts being adjusted by -1.31% over the past three months. During the same period, the stock price has changed by 9.68%.

Revenue Estimates for FY2026

Revise Downward

-1.31%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-1.35%

In Past 3 Month

Stock Price

Go Up

+9.68%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 67.50 USD with a low forecast of 60.00 USD and a high forecast of 73.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

60.00

Averages

67.50

High

73.00

Current: 0.000

Low

60.00

Averages

67.50

High

73.00

Evercore ISI

Outperform -> In Line

downgrade

$68 -> $62

2026-01-05

New

Reason

Evercore ISI

Price Target

$68 -> $62

2026-01-05

New

downgrade

Outperform -> In Line

Reason

Evercore ISI downgraded Bio-Techne to In Line from Outperform with a price target of $62, down from $68.

Deutsche Bank

Justin Bowers

Buy

maintain

$66 -> $72

2025-12-12

Reason

Deutsche Bank

Justin Bowers

Price Target

$66 -> $72

2025-12-12

maintain

Buy

Reason

Deutsche Bank analyst Justin Bowers raised the firm's price target on Bio-Techne to $72 from $66 and keeps a Buy rating on the shares. The firm cites accretion prospects of Bio-Techne's acquisition of Wilson Wolf for the target increase.

Baird

Catherine Ramsey Schulte

Neutral

downgrade

$62 -> $61

2025-11-06

Reason

Baird

Catherine Ramsey Schulte

Price Target

$62 -> $61

2025-11-06

downgrade

Neutral

Reason

Baird analyst Catherine Ramsey Schulte lowered the firm's price target on Bio-Techne to $61 from $62 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.

UBS

Buy

maintain

$65 -> $70

2025-11-06

Reason

UBS

Price Target

$65 -> $70

2025-11-06

maintain

Buy

Reason

UBS raised the firm's price target on Bio-Techne to $70 from $65 and keeps a Buy rating on the shares.

Evercore ISI

Outperform

NULL

downgrade

$72 -> $68

2025-11-06

Reason

Evercore ISI

Price Target

$72 -> $68

2025-11-06

downgrade

Outperform

NULL

Reason

Evercore ISI lowered the firm's price target on Bio-Techne to $68 from $72 and keeps an Outperform rating on the shares. The firm said it is trimming expectations for organic growth due to timing issue with cell therapy customers, yet the macro recovery thesis remains intact.

TD Cowen

Kyle Boucher

Buy

maintain

$65 -> $70

2025-10-14

Reason

TD Cowen

Kyle Boucher

Price Target

$65 -> $70

2025-10-14

maintain

Buy

Reason

TD Cowen analyst Kyle Boucher raised the firm's price target on Bio-Techne to $70 from $65 and keeps a Buy rating on the shares. The firm noted consensus estimates have moved lower since F4Q earnings, and while they lowered their estimates for 1H2026 given difficult year-over-year comparisons, they maintain their positive view on shares.

Valuation Metrics

The current forward P/E ratio for Bio-Techne Corp (TECH.O) is 29.51, compared to its 5-year average forward P/E of 41.74. For a more detailed relative valuation and DCF analysis to assess Bio-Techne Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

41.74

Current PE

29.51

Overvalued PE

52.58

Undervalued PE

30.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

29.42

Current EV/EBITDA

21.79

Overvalued EV/EBITDA

36.49

Undervalued EV/EBITDA

22.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

11.03

Current PS

7.51

Overvalued PS

14.29

Undervalued PS

7.77

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 2911.08% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 5004.01% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 2911.08% over the last month.

Sold

Bought

TECH News & Events

Events Timeline

No data

News

1.0

2025-12-23PRnewswire

Bio-Techne CEO to Present at 2026 J.P. Morgan Healthcare Conference on January 13

1.0

2025-12-23Newsfilter

Bio-Techne CEO Kim Kelderman to Present at 2026 J.P. Morgan Healthcare Conference on January 13

8.0

2025-12-19NASDAQ.COM

Significant Options Activity on Friday: ZBIO, TECH, OMER

People Also Watch

Frequently Asked Questions

What is Bio-Techne Corp (TECH) stock price today?

The current price of TECH is 65.7 USD — it has increased 1.73 % in the last trading day.

What is Bio-Techne Corp (TECH)'s business?

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.

What is the price predicton of TECH Stock?

What is Bio-Techne Corp (TECH)'s revenue for the last quarter?

Bio-Techne Corp revenue for the last quarter amounts to 286.56M USD, decreased -1.00 % YoY.

What is Bio-Techne Corp (TECH)'s earnings per share (EPS) for the last quarter?

Bio-Techne Corp. EPS for the last quarter amounts to 0.24 USD, increased 14.29 % YoY.

What changes have occurred in the market's expectations for Bio-Techne Corp (TECH)'s fundamentals?

How many employees does Bio-Techne Corp (TECH). have?

Bio-Techne Corp (TECH) has 3100 emplpoyees as of January 10 2026.

What is Bio-Techne Corp (TECH) market cap?

Today TECH has the market capitalization of 10.24B USD.